Alexander Maxwell Menzies

Alexander Maxwell Menzies

Top Cited Scholar 2023
Auto-generated profile, based on publicly available information

Alexander Maxwell Menzies

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JNJarushka Naidoo
Jarushka Naidoo
XWXuan Wang
Xuan Wang
KWKaitlin M. Woo
Kaitlin M. Woo
TITunc Iyriboz
Tunc Iyriboz
DHDarragh Halpenny
Darragh Halpenny
MHMatthew D. Hellmann
Matthew D. Hellmann
Purpose: Pneumonitis is an uncommon but potentially fatal toxicity of anti–programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described. Methods: Patients who received anti–PD-1/PD-L1 monotherapy or in combination with anti–cytotoxic T-cell lymphocyte associated antigen-4 mAb were identified at two institutions (Memorial Sloan Kettering Cancer Center: advanced solid cancers, 2009 to 2014, and Melanoma Institute of Australia: melanomas only, 2013 to 2015). Pneumonitis was diagnosed by the treating investigator; cases with confirmed malignant lung infiltration or infection were excluded. Clinical, radiologic, and pathologic features of pneumonitis were collected. Associations among pneumonitis incidence, therapy received, and underlying malignancy were examined with Fisher’s exact test as were associations between pneumonitis features and outcomes. Results: Of 915 patients who received anti–PD-1/PD-L1 mAbs, pneumonitis developed in 43 (5%; 95% CI, 3% to 6%; Memorial Sloan Kettering Cancer Center, 27 of 578 [5%]; Melanoma Institute of Australia, 16 of 337 [5%]). Time to onset of pneumonitis ranged from 9 days to 19.2 months. The incidence of pneumonitis was higher with combination immunotherapy versus monotherapy (19 of 199 [10%] v 24 of 716 [3%]; P < .01). Incidence was similar in patients with melanoma and non–small-cell lung cancer (overall, 26 of 532 [5%] v nine of 209 [4%]; monotherapy, 15 of 417 v five of 152 [ P = 1.0]; combination, 11 of 115 v four of 57 [ P = .78]). Seventy-two percent (31 of 43) of cases were grade 1 to 2, and 86% (37 of 43) improved/resolved with drug holding/immunosuppression. Five patients worsened clinically and died during the course of pneumonitis treatment; proximal cause of death was pneumonitis (n = 1), infection related to immunosuppression (n = 3), or progressive cancer (n = 1). Radiologic and pathologic features of pneumonitis were diverse. Conclusion: Pneumonitis associated with anti–PD-1/PD-L1 mAbs is a toxicity of variable onset and clinical, radiologic, and pathologic appearances. It is more common when anti–PD-1/PD-L1 mAbs are combined with anti–cytotoxic T-cell lymphocyte associated antigen-4 mAb. Most events are low grade and improve/resolve with drug holding/immunosuppression. Rarely, pneumonitis worsens despite immunosuppression, and may result in infection and/or death.

1 April 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GLGeorgina Venetia Long
Georgina Venetia Long
AMAlexander M. Menzies
Alexander M. Menzies
ANAdnan M. Nagrial
Adnan M. Nagrial
LHLauren E. Haydu
Lauren E. Haydu
AHAnne L. Hamilton
Anne L. Hamilton
RKRichard F. Kefford
Richard F. Kefford
Purpose: To assess the frequency and type of oncogenic BRAF mutations in metastatic melanoma and correlate BRAF status with clinicopathologic features and outcome. Patients and Methods: Consecutive BRAF-tested Australian patients with metastatic melanoma (n = 197) were observed prospectively. A comprehensive range of clinicopathologic variables were correlated with BRAF mutation status, and a survival analysis was conducted. Results: Forty-eight percent of patients had a BRAF mutation; 70 patients (74%) had V600E, 19 (20%) had V600K, and six (6%) had other genotypes. Other than age at diagnosis of distant metastasis (median age, 56 v 63 years for BRAF-mutant v BRAF wild-type patients, respectively; P < .001), there was no significant difference in clinical features of patients with metastatic melanoma by mutation status. Features of the antecedent primary melanoma significantly associated with a BRAF mutation (P < .05) were histopathologic subtype, presence of mitoses, single or occult primary melanoma, truncal location, and age at diagnosis of primary tumor ≤ 50 years. The interval from diagnosis of first-ever melanoma to distant metastasis was not significantly different between BRAF-mutant and BRAF wild-type patients; however, the median survival of patients with newly diagnosed metastatic melanoma was 5.7 months for BRAF-mutant patients not treated with a BRAF inhibitor, 8.5 months for BRAF wild-type patients, and not reached for BRAF-mutant patients treated with a BRAF inhibitor. Conclusion: V600K mutations comprised 20% of BRAF mutations. Characteristics of the antecedent primary melanoma and age at diagnosis differed in BRAF-mutant and BRAF wild-type patients. The presence of mutant BRAF had no impact on the disease-free interval from diagnosis of first-ever melanoma to first distant metastasis; however, it may have impacted survival thereafter.

1 May 2018 in The Lancet Oncology
Verified
Journal Article
Closed access
GLGeorgina Venetia Long
Georgina Venetia Long
VAVictoria Atkinson
Victoria Atkinson
SLSerigne Lo
Serigne Lo
Shahneen K. SandhuShahneen K. Sandhu
Shahneen K. Sandhu
AGAlexander D Guminski
Alexander D Guminski
GMGrant A McArthur
Grant A McArthur

29 September 2016 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
AMA. M. Menzies
A. M. Menzies
DJD. B. Johnson
D. B. Johnson
SRS. Ramanujam
S. Ramanujam
VAV. G. Atkinson
V. G. Atkinson
AWA. N. M. Wong
A. N. M. Wong
GLGeorgina Venetia Long
Georgina Venetia Long
Anti-PD-1 antibodies (anti-PD-1) have clinical activity in a number of malignancies. All clinical trials have excluded patients with significant preexisting autoimmune disorders (ADs) and only one has included patients with immune-related adverse events (irAEs) with ipilimumab. We sought to explore the safety and efficacy of anti-PD-1 in such patients. Patients with advanced melanoma and preexisting ADs and/or major immune-related adverse events (irAEs) with ipilimumab (requiring systemic immunosuppression) that were treated with anti-PD-1 between 1 July 2012 and 30 September 2015 were retrospectively identified. One hundred and nineteen patients from 13 academic tertiary referral centers were treated with anti-PD-1. In patients with preexisting AD (N = 52), the response rate was 33%. 20 (38%) patients had a flare of AD requiring immunosuppression, including 7/13 with rheumatoid arthritis, 3/3 with polymyalgia rheumatica, 2/2 with Sjogren’s syndrome, 2/2 with immune thrombocytopaenic purpura and 3/8 with psoriasis. No patients with gastrointestinal (N = 6) or neurological disorders (N = 5) flared. Only 2 (4%) patients discontinued treatment due to flare, but 15 (29%) developed other irAEs and 4 (8%) discontinued treatment. In patients with prior ipilimumab irAEs requiring immunosuppression (N = 67) the response rate was 40%. Two (3%) patients had a recurrence of the same ipilimumab irAEs, but 23 (34%) developed new irAEs (14, 21% grade 3–4) and 8 (12%) discontinued treatment. There were no treatment-related deaths. In melanoma patients with preexisting ADs or major irAEs with ipilimumab, anti-PD-1 induced relatively frequent immune toxicities, but these were often mild, easily managed and did not necessitate discontinuation of therapy, and a significant proportion of patients achieved clinical responses. The results support that anti-PD-1 can be administered safely and can achieve clinical benefit in patients with preexisting ADs or prior major irAEs with ipilimumab.

1 March 2018 in The Lancet Oncology
Verified
Journal Article
Closed access
JMJennifer L. McQuade
Jennifer L. McQuade
CDCarrie R Daniel
Carrie R Daniel
KHKenneth R Hess
Kenneth R Hess
CMCarmen Mak
Carmen Mak
DWDaniel Y Wang
Daniel Y Wang
MDMichael A Davies
Michael A Davies

1 February 2016 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
DJDouglas B Johnson
Douglas B Johnson
RSRyan J. Sullivan
Ryan J. Sullivan
POPatrick A. Ott
Patrick A. Ott
MCMatteo S. Carlino
Matteo S. Carlino
NKNikhil I. Khushalani
Nikhil I. Khushalani
JCJoseph I. Clark
Joseph I. Clark
Ipilimumab is a monoclonal antibody to cytotoxic T-lymphocyte antigen 4 (CTLA-4) that induces antitumor immune responses by removing a key negative regulator of T cell activation. This antibody was the first agent to demonstrate improved overall survival for patients with advanced melanoma and received regulatory approval in 2011.1,2 Furthermore, durable benefits have been observed, with approximately 20% of patients surviving at least 5 years.3,4